Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder

<p>NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) — Yamo Pharmaceuticals LLC (Yamo), a clinical stage pharmaceutical company, announced today that it has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder (ASD). Top-line data from the trial are expected in August 2024. With the completion of […]</p>
<p>The post <a href="https://forextv.com/top-news/yamo-pharmaceuticals-enrolls-final-patient-in-phase-2-study-evaluating-l1-79-to-treat-the-core-symptoms-of-autism-spectrum-disorder/">Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>